Revolution Medicines (NASDAQ: RVMD)
Revolution Medicines Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Revolution Medicines Company Info
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
News & Analysis
Why Revolution Medicines Stock Is Crashing Today
Investors were disappointed by Revolution Medicines' data, presented at ESMO.
Why Shares of Revolution Medicines Were Popping on Friday
The company released positive phase 1/1b trial data on two cancer therapies.
This 2020 Biotech IPO Is Poised to Break Out in 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Investors Scrambled to Buy This Biotech IPO
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.